An ETP-like immunophenotype is associated with an inferior prognosis in HOXAPos, but not HOXANeg adult T-ALL. The results of survival analyses after separation of the HOXAPos and HOXANeg groups according to the presence or absence of an ETP-like immunophenotype are shown. The 5-year survival figures were as follows: (A) overall survival (OS) for HOXAPos ETP 31.3% (95% CI, 11.4% – 53.7%), HOXAPos non-ETP 66.7% (95% CI, 42.5% – 82.5%), HOXANeg ETP 74.2% (95% CI, 45% – 89.4%), HOXANeg non-ETP 57.2% (95% CI, 46.1% – 66.9%). (B) Event-free survival (EFS) for HOXAPos ETP 25% (95% CI, 10.2% – 43.1%), HOXAPos non-ETP 52.7% (95% CI, 35.5% – 67.4%), HOXANeg ETP 60.8% (95% CI, 39.4% – 76.6%), HOXANeg non-ETP 50.7% (95% CI, 41.1% – 59.5%). (C) Disease-free survival (DFS) for HOXAPos ETP 28.6% (95% CI, 11.7% – 48.2%), HOXAPos non-ETP 53.6% (95% CI, 35.9% – 68.5%), HOXANeg ETP 64.7% (95% CI, 43.1% – 79.8%), HOXANeg non-ETP 52.2% (95%CI, 42.1% – 61.3%). (D) Cumulative incidence of relapse (CIR) for HOXAPos ETP 53.7% (95% CI, 34.3% – 75.6%), HOXAPos non-ETP 25.4% (95% CI, 13.6% – 44.4%), HOXANeg ETP 29.2% (95% CI, 15.1% – 51.6%), HOXANeg non-ETP 39.2% (95% CI, 30.6% – 49.3%).